Otic Pharma

Foam-based Products for the Treatment of Ear, Nose, and Throat Disorders

Health Tech & Life Sciences
Acquired (Inactive) by Novus Therapeutics on May 2017 - closed due to acquisition

Company Overview

Snapshot

Founded in January 2008, Otic Pharma operates with 1–10 employees. The company raised $5.25M across four funding rounds from five investors, with Peregrine Ventures leading one of the rounds. Otic Pharma was acquired by Novus Therapeutics in May 2017.

Business overview

Otic Pharma Ltd develops therapeutic products for ear, nose, and throat (ENT) disorders, leveraging its proprietary FoamOtic platform. The company's core technology focuses on foam-based drug delivery to enable sustained drug exposure, fewer administrations, and lower doses for treatments. Otic Pharma serves the pharmaceuticals market, with products like FoamOtic Externa for acute otitis externa and pipeline products for chronic sinusitis and otitis media in both humans and animals.

Strategic signal

In May 2017, Otic Pharma completed its merger with Tokai Pharmaceuticals, marking a significant strategic exit for the company. This acquisition by Novus Therapeutics indicates a successful validation of Otic Pharma's foam-based drug delivery platform and its therapeutic pipeline, signaling a positive outcome for investors and a potential integration of its technology into a larger pharmaceutical entity.

Company Intelligence Q&A

What was the most significant corporate event for Otic Pharma?
Otic Pharma was acquired by Novus Therapeutics in May 2017, following its merger with Tokai Pharmaceuticals.
When was Otic Pharma founded?
Otic Pharma was founded in January 2008.
What is Otic Pharma's primary product?
Otic Pharma's leading investigational drug is FoamOtic Externa, a foam-based version of ciprofloxacin for the treatment of acute otitis externa (AOE).
Which investors participated in Otic Pharma's funding rounds?
Otic Pharma received funding from investors including OrbiMed and Pontifax
What was a key development in Otic Pharma's clinical trials?
In January 2015, Otic Pharma announced positive results from a Phase 2 trial of FoamOtic Externa, its once-a-day, single antibiotic, steroid-free product for Acute Otitis Externa (AOE).

External links